Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

mAbs

Showing results (1531-1540 of 1,779) with videos related to

Pageof 178
Sort By:
Mabs|October 16, 2015
Intellectual property issues of immune checkpoint inhibitorsUlrich Storz
Mabs|February 9, 2016
Combining phage display with de novo protein sequencing for reverse engineering of monoclonal antibodiesKeith W Rickert, Luba Grinberg, Robert M Woods, et al.
Mabs|February 9, 2016
Inhibition of CD73 AMP hydrolysis by a therapeutic antibody with a dual, non-competitive mechanism of actionJames C Geoghegan, Gundo Diedrich, Xiaojun Lu, et al.
Mabs|January 21, 2016
Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long-term infusion in combination with IL-2Nikolai Siebert, Christin Eger, Diana Seidel, et al.
Mabs|February 27, 2016
The use of lectin microarray for assessing glycosylation of therapeutic proteinsLei Zhang, Shen Luo, Baolin Zhang
Mabs|March 2, 2016
Pregnancy-specific glycoprotein expression in normal gastrointestinal tract and in tumors detected with novel monoclonal antibodiesAileen Houston, John M Williams, Tihana Lenac Rovis, et al.
Mabs|February 25, 2016
Differential killing of CD56-expressing cells by drug-conjugated human antibodies targeting membrane-distal and membrane-proximal non-overlapping epitopesYang Feng, Yanping Wang, Zhongyu Zhu, et al.
Mabs|September 2, 2015
Anticancer activity of TTAC-0001, a fully human anti-vascular endothelial growth factor receptor 2 (VEGFR-2/KDR) monoclonal antibody, is associated with inhibition of tumor angiogenesisDong Geon Kim, Younggeon Jin, Juyoun Jin, et al.
Mabs|September 5, 2015
The interplay of non-specific binding, target-mediated clearance and FcRn interactions on the pharmacokinetics of humanized antibodiesAmita Datta-Mannan, Jirong Lu, Derrick R Witcher, et al.
Mabs|September 5, 2015
Therapeutic drug monitoring of eculizumab: Rationale for an individualized dosing schedulePhilippe Gatault, Guillaume Brachet, David Ternant, et al.
Pageof 178

Showing results (1531-1540 of 1,779) with videos related to

Sort By:
Pageof 178
Mabs|October 16, 2015
Intellectual property issues of immune checkpoint inhibitorsUlrich Storz
Mabs|February 9, 2016
Combining phage display with de novo protein sequencing for reverse engineering of monoclonal antibodiesKeith W Rickert, Luba Grinberg, Robert M Woods, et al.
Mabs|February 9, 2016
Inhibition of CD73 AMP hydrolysis by a therapeutic antibody with a dual, non-competitive mechanism of actionJames C Geoghegan, Gundo Diedrich, Xiaojun Lu, et al.
Mabs|January 21, 2016
Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long-term infusion in combination with IL-2Nikolai Siebert, Christin Eger, Diana Seidel, et al.
Mabs|February 27, 2016
The use of lectin microarray for assessing glycosylation of therapeutic proteinsLei Zhang, Shen Luo, Baolin Zhang
Mabs|March 2, 2016
Pregnancy-specific glycoprotein expression in normal gastrointestinal tract and in tumors detected with novel monoclonal antibodiesAileen Houston, John M Williams, Tihana Lenac Rovis, et al.
Mabs|February 25, 2016
Differential killing of CD56-expressing cells by drug-conjugated human antibodies targeting membrane-distal and membrane-proximal non-overlapping epitopesYang Feng, Yanping Wang, Zhongyu Zhu, et al.
Mabs|September 2, 2015
Anticancer activity of TTAC-0001, a fully human anti-vascular endothelial growth factor receptor 2 (VEGFR-2/KDR) monoclonal antibody, is associated with inhibition of tumor angiogenesisDong Geon Kim, Younggeon Jin, Juyoun Jin, et al.
Mabs|September 5, 2015
The interplay of non-specific binding, target-mediated clearance and FcRn interactions on the pharmacokinetics of humanized antibodiesAmita Datta-Mannan, Jirong Lu, Derrick R Witcher, et al.
Mabs|September 5, 2015
Therapeutic drug monitoring of eculizumab: Rationale for an individualized dosing schedulePhilippe Gatault, Guillaume Brachet, David Ternant, et al.
Pageof 178